Boston, MA 04/05/2013 (wallstreetpr) – CEL-SCI Corporation (NYSEAMEX:CVM) is a global leader in the research and development of cancer treatment and drugs, by utilizing the immune system of the body. The company is presently involved in a pioneering investigation therapy called Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. Additionally, the company is involved in several immunological projects. The latest stress is on the immunization as a possible treatment for H1N1 hospitalized patients- a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its groundbreaking LEAPS technology platform.
The aggregate market value of the voting stock held by non-affiliates of the CVM is based on the closing sales price of the common stocks on March 31, 2012, which was $120,199,660. Currently trading at $0.278, up by 0.51%. Yesterday, its stock value reached as high as $0.28 and dipped at $0.2426. Considering the quoted rates of the previous day, the market share price gained 10.26% yesterday, with a significant volume rise in the trading. A study of last three months trading revealed that on an average around 1.2 million shares of CEL-CSI were traded on NASDAQ. A further study of the year long trading reveals, that the value of the stocks reached an all time high of $0.58 and the lowest quoted rate was $0.205. With a market capitalization of around $85 million, the company has made a singular presence of trading on the stock exchange.
With revolutionizing technology in new age immunological studies, with a view to resolve the long craving demands of Medical Science, CEL-SCI is all set to draw its own horizon in the global markets. Its current presence on the NASDAQ is a robust indication of its ambitions and organizational growth. The principal traders of the NASDAQ have shown a considerable interest in this company. Subsequently, investing in CVM stocks will be a brilliant choice for investors who have a vision of the future. The rest is for the investors to find out in the coming times.
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com